Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. more
Time Frame | ACST | Sector | S&P500 |
---|
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 196.00K | 13.00K | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":6.63,"profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Cost of Revenue | 2.32M | 76.00K | 15.59M | 52.16M | 11.00K | [{"date":"2020-03-31","value":4.45,"profit":true},{"date":"2021-03-31","value":0.15,"profit":true},{"date":"2022-03-31","value":29.89,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":0.02,"profit":true}] |
Gross Profit | (2.32M) | 120.00K | (15.59M) | (52.16M) | (11.00K) | [{"date":"2020-03-31","value":-1933.33,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-12990.83,"profit":false},{"date":"2023-03-31","value":-43462.5,"profit":false},{"date":"2024-03-31","value":-9.17,"profit":false}] |
Gross Margin | (Infinity%) | 61.22% | (119915.38%) | (Infinity%) | (Infinity%) | [{"date":"2020-03-31","value":null,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-195861.79,"profit":false},{"date":"2023-03-31","value":null,"profit":false},{"date":"2024-03-31","value":null,"profit":false}] |
Operating Expenses | 24.44M | 10.84M | 15.34M | 18.25M | 11.30M | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":44.34,"profit":true},{"date":"2022-03-31","value":62.77,"profit":true},{"date":"2023-03-31","value":74.67,"profit":true},{"date":"2024-03-31","value":46.24,"profit":true}] |
Operating Income | (24.44M) | (10.72M) | (15.59M) | 15.72M | (11.31M) | [{"date":"2020-03-31","value":-155.43,"profit":false},{"date":"2021-03-31","value":-68.15,"profit":false},{"date":"2022-03-31","value":-99.15,"profit":false},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":-71.95,"profit":false}] |
Total Non-Operating Income/Expense | (1.03M) | (11.42M) | 4.93M | (45.39M) | (3.71M) | [{"date":"2020-03-31","value":-20.91,"profit":false},{"date":"2021-03-31","value":-231.44,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-919.75,"profit":false},{"date":"2024-03-31","value":-75.09,"profit":false}] |
Pre-Tax Income | (25.51M) | (19.68M) | (10.47M) | (51.97M) | (14.63M) | [{"date":"2020-03-31","value":-2551300000,"profit":false},{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-1046700000,"profit":false},{"date":"2023-03-31","value":-5197100000,"profit":false},{"date":"2024-03-31","value":-1463000000,"profit":false}] |
Income Taxes | 247.00K | (127.00K) | (648.00K) | (9.54M) | (1.78M) | [{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-51.42,"profit":false},{"date":"2022-03-31","value":-262.35,"profit":false},{"date":"2023-03-31","value":-3863.16,"profit":false},{"date":"2024-03-31","value":-719.43,"profit":false}] |
Income After Taxes | (25.76M) | (19.55M) | (9.82M) | (42.43M) | (12.85M) | [{"date":"2020-03-31","value":-2576000000,"profit":false},{"date":"2021-03-31","value":-1955100000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false}] |
Income From Continuous Operations | (25.51M) | (19.68M) | (9.82M) | (42.43M) | (12.85M) | [{"date":"2020-03-31","value":-2551300000,"profit":false},{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (25.76M) | (19.68M) | (9.82M) | (42.43M) | (12.85M) | [{"date":"2020-03-31","value":-2576000000,"profit":false},{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false}] |
EPS (Diluted) | (2.12) | (0.92) | (0.31) | (4.20) | (1.45) | [{"date":"2020-03-31","value":-211.58,"profit":false},{"date":"2021-03-31","value":-92,"profit":false},{"date":"2022-03-31","value":-31,"profit":false},{"date":"2023-03-31","value":-420,"profit":false},{"date":"2024-03-31","value":-145,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACST | |
---|---|
Current Ratio | 6.01 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACST | |
---|---|
ROA (LTM) | -11.62% |
ROE (LTM) | -18.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACST | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACST | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 208.39 |
P/B | 0.59 |
Price/FCF | NM |
EV/R | 5.50 |
EV/Ebitda | NM |
Acasti Pharma Inc (ACST) share price today is $
Yes, Indians can buy shares of Acasti Pharma Inc (ACST) on Vested. To buy Acasti Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACST stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Acasti Pharma Inc (ACST) via the Vested app. You can start investing in Acasti Pharma Inc (ACST) with a minimum investment of $1.
You can invest in shares of Acasti Pharma Inc (ACST) via Vested in three simple steps:
The 52-week high price of Acasti Pharma Inc (ACST) is $3.6. The 52-week low price of Acasti Pharma Inc (ACST) is $1.98.
The price-to-earnings (P/E) ratio of Acasti Pharma Inc (ACST) is
The price-to-book (P/B) ratio of Acasti Pharma Inc (ACST) is 0.59
The dividend yield of Acasti Pharma Inc (ACST) is 0.00%
The market capitalization of Acasti Pharma Inc (ACST) is $34.17M
The stock symbol (or ticker) of Acasti Pharma Inc is ACST